Citius Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) on May 24, 2021. The report details the results of a special meeting of stockholders held on the same date to vote on three specific proposals outlined in a proxy statement filed on April 12, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on the following proposals:
- Proposal 2 (Adjournment): Approved to allow the company to solicit additional proxies if necessary for Proposal 1.
- For: 55,978,590 shares
- Against: 13,875,775 shares
- Abstaining: 852,570 shares
- Broker Non-Votes: 0
- Proposal 3 (2021 Omnibus Stock Incentive Plan): Approved.
- For: 25,524,515 shares
- Against: 4,550,381 shares
- Abstaining: 532,806 shares
- Broker Non-Votes: 40,099,233 shares
- Proposal 1 (Increase in Authorized Common Stock): The meeting was adjourned regarding this proposal. Management noted that the majority of shares voted to date favored approval, but the final results are pending. The meeting was rescheduled for June 21, 2021, at 8:00 a.m. Eastern Time.
Outlook, Risks, and Management Commentary
Management indicated that the filing will be amended to report the final results of Proposal 1 once the adjourned meeting concludes. No specific financial risks, contingencies, or unusual items were disclosed in this text.
Investor Verification Checklist
- Verify the final outcome of Proposal 1 (increase in authorized shares) in the amended 8-K following the June 21, 2021 meeting.
- Review the definitive proxy statement filed on April 12, 2021, for detailed terms of the 2021 Omnibus Stock Incentive Plan.
- Confirm the total number of shares outstanding to assess the impact of the potential increase in authorized shares.